Gliomas display cellular hierarchies with self-renewing tumorigenic glioma stem cells (GSCs) at the apex. The GSC niches function as a regulator of GSC maintenance, however, the exact components of GSC niches that mediate this process are still far from fully defined. Here, we showed that glioma cells with aberrant mesenchymal phenotypes constitute a mesenchymal niche for GSCs. Using patient-derived specimens, we demonstrated that the paracrine PGI signaling, initiated by mesenchymal glioma cells, induces the self-renewal and tumorigenic potentials of GSCs through induction of KLF4. Treatment of intracranial orthotopic xenografts with shPGI or shKLF4 leads to less lethal potency. Our data therefore suggest that blockade of the PGI-KLF4 pathway may provide a therapeutic strategy against GSC niches.
Glioma is a particularly devastating and lethal form of tumor derived from glia or their precursors within the central nervous system. The identification of distinct glioma subtypes based on gene expression profiling has increased our understanding of the molecular basis of differences in patient survival rate. For example, gene expression studies have established that overexpression of a 'mesenchymal' gene expression signature (MGES) and loss of a proneural signature (PNGES) co-segregate the poor prognosis group of glioma patients [1, 2] . Indeed, a mesenchymal phenotype is the hallmark of tumor aggressiveness in malignant gliomas [3] . However, little is known about the key molecular alterations that are responsible for driving glioma progression in mesenchymal subgroups.
A key feature of malignant gliomas is the cellular heterogeneity of the bulk tumor mass. There is growing evidence that an individual cellular subpopulation, known as glioma stem cells (GSCs), might possess self-renewing, multipotent, and tumor-initiating capabilities [4] [5] [6] . Recently, compelling evidence has related mesenchymal differentiation to the emergence of cancer stem cell (CSC)-like phenotype [7] [8] [9] . Similar phenomena have also been observed in malignant gliomas. For example, a shift to a mesenchymal phenotype is frequently observed in recurrent gliomas from the same patient [1] . Meanwhile, the percentage of GSCs was significantly higher in recurrent gliomas than that in autologous primary tissues [10] . Then, a question arises whether a particular process of mesenchymal metaplasia will be sufficient for remolding all the cellular appearances of CSCs. Mesenchymal differentiation is a reversible process that can be induced or reversed by various stimuli in tumor microenvironment [11] [12] [13] , whereas the current CSC model presumes an irreversible differentiation in tumor tissues [14, 15] . We proposed that mesenchymal differentiation-induced CSC generation may be rather a sideeffect than a true effect. This opinion seems to be supported by a recent report showing that no changes in CSC marker expression have been detected after mesenchymal induction in K-ras-dependent pancreatic cancer cells [16] .
Instructive cues to maintain GSCs are generated by both intrinsic networks and the niche microenvironment. Intrinsic regulation of GSCs occurs through key proliferative and survival pathways such as c-Myc, Oct4, Olig2, and Bmi1 [17] . Extrinsically, several models have been employed to interrogate the nature of communication between GSCs and their niches [18, 19] . Apart from the stromal cells (inflammatory cells, endothelial cells, and glial cells) which compose the GSCs niche, differentiated glioma cells defining the tumor mass should also be considered within its immediate tumor microenvironment. We hypothesized that within malignant gliomas undergoing mesenchymal transition, GSCs have gained an ability to adjust their self-renewal ability to given environmental influences, leading to the aberrant expansion of GSCs pool. Here, we focus on a better understanding of the regulatory mechanism of mesenchymal glioma cells on the stemness of GSCs, which may help to identify the potential therapeutic targets.
Materials and methods
Tumor samples and cell lines. All human glioma specimens were collected from Huashan Hospital. The clinical protocol was approved by Huashan Institutional Review Board (HIRB) with informed consent. Fresh glioma tissues obtained from operating room were processed within 30min after surgical resection. Briefly, minced pieces of human glioma samples were digested with 200U/ml collagenase I (Sigma) and 500U/ml DNAse I (Sigma) in PBS for 2h at 37˚C. The singlecell suspension was filtered through a 70mm cell strainer (BD Falcon) and washed with PBS. Finally, cells were resuspended and subsequently cultured in DMEM with 10% FBS (for primary cultures) or in Neurobasal medium (Invitrogen) (for oncospheres).
Oncosphere initiation assays. To evaluate GSC self-renewal, oncosphere initiation assays were performed in the single-cell suspensions. Equal number of cells was seeded at low cell density (4 cells/μl) in wells of a 96-well plate. Number of spheres was quantified after 14 days. Tumor spheres were then disaggregated and reseeded to evaluate self-renewal by formation of quaternary oncospheres.
Quantitative real-time PCR. qPCR was performed using Taqman probes from Applied Biosystems, according to the manufacturer's recommendations. Reactions were carried out in an ABI 7000 sequence detector (Perkin Elmer) and results were expressed as fold change calculated by the ΔΔCt method relative to the control sample or to the first sample quantified. GAPDH was used as internal normalization controls.
Luciferase reporter assays. Cells in 24-well plates were transiently transfected with different KLF4 promoter reporter constructs and pRLTK Renilla luciferase plasmid (Promega) using Fugene 6 (Roche). Cell extracts were prepared 48h after transfection, and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega).
Immunocytochemistry and immunohistochemistry.
Using antibodies against CD133 (miltenyi), Fibronectin (Chemicon), ki-67 (Sigma), FSTL1 (Abcam) fibronectin (Santa Cruz), YKL40 (Quidel), gp78 (Santa Cruz), immunofluorescence microscopy analysis of oncospheres, primary glioma cells and sections of freshly frozen glioma samples was performed as described [20] . Immunohistochemistry of glioma sections was performed as described previously using the antibody against KLF4 (Chemicon) [20] .
Immunoblotting. Total protein was extracted from cells using RIPA lysis buffer (Santa Cruz). Protein extract (50 μg/lane) was electrophoresed, transferred to PVDF membranes and incubated overnight with primary antibodies against PGI (Sigma), KLF4 (Sigma), COL5A1 (Santa Cruz), fibronectin (Santa Cruz), YKL40 (Bio Scientific) respectively. Membranes were then treated with the appropriate HRP-conjugated secondary antibodies (Invitrogen). Detection was performed using the reagents provided in the ECL+Plus kit (GE healthcare).
Animal studies. The indicated glioma cells were stereotactically inoculated into the corpus striatum of right brain hemisphere (1mm anterior and 1.8mm lateral to the bregma; 2.5 mm intraparenchymal) of 6-8 weeks old NOD/SCID mice. Immediately following inoculation, implanted animals were transferred to the intravital imaging system (Nikon) and imaged to obtain a baseline measurement. Data analysis was performed using Metamorph imaging software (Universal Imaging). For intracranial injections, when the newly formed tumor reached 0.5-0.6cm in diameter, mice were placed in a stereotactic frame under anesthesia. The striatum was targeted unilaterally on the right hemisphere using a 30-G needle (Hamilton) connected to a Hamilton 5μl syringe. The stereotactic coordinates for the microinjections were: +0.6mm anterior and +1mm lateral to the bregma. shRNA vectors, mixed with liposome at the ratio of 1:1 for transfection, were injected at a rate of 1 μl/min over 2 minutes, twice a week, for two weeks.
Statistical analysis. Statistics were calculated by SPSS software. The results are presented as mean ± standard error (SEM). ANOVA, Student's t-test analysis and Dunnett's multiple comparison tests were used to compare mean values. A P-value of less than 0.05 was defined as statistical significance.
Results
The degree of mesenchymal phenotype correlates with the quantity of the CD133+ GSCs in human gliomas. As shown in Fig1A and Table1, positive immunoreactivity and immunostaining intensity for either YKL40 or fibronectin (FN) (well-established mesenchymal proteins expressed in gliomas) were positively associated with histopathological grade, with expression being highest in GBMs. Noteworthy, tumors with aberrant expression of YKL40/FN were associated with increased CD133 index ( Fig 1B and Table 2 ). The association rate was significantly higher in high-grade gliomas (grade III and IV) versus lower-grade ones (grade II). Among those HGGs with high or moderate levels of YKL40/FN staining, 31 of 39 had a CD133 staining ≥2+ intensity. However, in the lowergrade gliomas with similar immunostaining of YKL40/FN, only 2 of 8 had a CD133 staining ≥2+ intensity.
We sought to determine if the CD133+ cells in gliomas are cancer cells or entrapped normal neural stem cells. Follistatin-like1 (FSTL1) has been identified as a diagnostic hallmark of primary GBMs [21] . 66.8%±9.7% of the CD133+ cells co-expressed FSTL1, confirming that they are GBM cells. Indeed, CD133/Ki-67 double immunostaining showed that 29.1%±11.6% of CD133+ cells appear to possess aberrant proliferative capacity, suggesting further that they are cancer cells ( Fig 1C) .
The mesenchymal environment in malignant gliomas promotes the self-renewal capacity of GSCs. We next compared the stemness properties of GSCs derived from different subtypes of gliomas. Glioma cells were isolated from three grade II astrocytomas without mesenchymal phenotype (AC1-3), four GBMs without mesenchymal phenotype (GBM1-4), and four mesenchymal GBMs (GBM5-8), under conditions that promote stem cell growth. Within 14 days, all individual cells produced nonadherent, multicellular oncospheres which express CD133 and nestin (Fig 2A) . The more mesenchymal phenotype expressed, the quicker the cells grew and the more tumor spheres formed (Fig 2B) . Moreover, oncospheres from gliomas without mesenchymal phenotypes showed limited expansion and cannot be maintained beyond passage 2 (<2 passages), whereas all mesenchymal GBMs yielded sphere cells with extended passages (>4 passages) (Fig 2C) .
Mesenchymal differentiation contributes to enrichment of CSCs in malignant epithelial tumors. We isolated the CD133-cells from two grade II astrocytomas without mesenchymal phenotypes (AC1 and AC2) and transfected them with pcDNA3.1-Twist1 (Fig S2A) . The CD133-subpopulations undergoing mesenchymal change displayed no enhancement in either oncosphere-forming ability (Fig S2B) or expression of GSC markers (Fig S2C) , thereby precluding the possibility that the enhanced GSC self-renewal in mesenchymal gliomas is a direct consequence of mesenchymal differentiation.
To figure out whether the differential stem-like properties is attributed to the GSCs themselves or the mesenchymal phenotype, we transferred AC1 oncospheres to the base of culture wells while the upper transwell compartment was seeded with the AC1 CD133-/pcDNA3.1-Twist1 or control cells (Fig 2D) . This transwell system allows the exchange of diffusible factors, but not cells, between chambers. AC1 oncospheres that were cocultured with the AC1 CD133-/pcDNA3.1-Twist1 cells formed up to 4.2 times as many oncopsheres as those grown in the presence of control cells. Moreover, these sphere cells were significantly more likely to generate quaternary tumor spheres as compared with those from control cocultures (Fig 2E) , suggesting that mesenchymal condition is critical for maintaining the selfrenewal capacity of GSCs.
PGI secreted by mesenchymal glioma cells promotes GSCs self-renewal. To perform a comparative analysis of the proteins differentially expressed in the active fraction of mesenchymal glioma cells, the AC1 CD133-/pCDNA3.1-Twist1 and control cells were incubated in serum-free media for 3 days, after which relative protein abundance in culture supernatants was determined using label-free proteomic software and Mascot 2.2. When comparing the Twist1-overexpressing group with the control group, 36 proteins showed difference of at least 1.5-fold. Of these, phosphoglucose isomerase (PGI) was found to have a more than four-fold difference between the two groups (Table S1 ). Our study further showed that PGI secretion in the supernatant of mesenchymal GBMs was significantly higher as compared to that of lower-grade gliomas without mesenchymal phenotype and non-mesenchymal GBMs. A similar result was observed in the whole lysed cells (Fig 3A) . In all cases of normal brain tissue adjacent to the tumor, there was only negligible PGI expression (data not shown). The effects of PGI are mediated via its specific receptor, gp78 [22] . GSCs expressed elevated levels of gp78 in comparison to the nonstem glioma cells, consistent with the mRNA expression data (Fig 3B) . Although we detected PGI expression in GSCs, PGI mRNA levels (Fig S2A) , as well as secreted PGI levels ( Fig  S2B) were remarkably higher in the non-stem glioma cells than the matched GSCs. These data suggest that paracrine signaling between the non-stem glioma cells and GSCs may predominate in the mesenchymal gliomas.
We next assessed the effect of PGI on GSCs self-renewal properties. Patient-derived oncospheres from a low-grade glioma without mesenchymal phenotype (AC1), a GBM without mesenchymal phenotype (GBM2) and a mesenchymal GBM (GBM5) were dissociated into single cells and treated with PGI or left untreated for 14 days. Treatment with PGI not only enhanced the number of oncospheres, but also increased the sphere formation efficiency with quaternary oncospheres (Fig 3C) . PGI did not affect BrdU incorporation of the treated oncospheres (Fig S3) . The effect of PGI was blocked when the gp78 blocking peptide, P0973, was added concomitantly with PGI (Fig 3C) . In addition, there was a dose-dependent effect of PGI on the number of oncospheres with extended self-renewal capacities (Fig 3D) , and the effect of PGI on self-renewal was observed even when cells were plated at very low density (Fig 3E) . In agreement with the suggested effects of PGI signaling, PGI also increased the size of the CD133+ GSCs pool, which could be largely abolished by pre-treating with P0973 (Fig 3F) .
PGI induces KLF4 expression in GSCs. In order to identify which PGI responses mediate GSCs self-renewal, AC1 and AC2 oncospheres were treated with PGI, gp78 inhibitor, or a combination of both for 3 hr, after which a transcriptomic analysis was performed. Among the 9 common gene responses to PGI between AC1 and AC2 sphere cells (Fig 4A; Table S2 ), zinc finger Kruppel-like transcription factor 4 (KLF4) stood out as for its role in cancer formation and stem cell regulation [23] [24] [25] . We firstly determined whether induction of KLF4 by PGI is a common phenomenon that takes place in most human gliomas. After the CD133-cells derived from 8 human gliomas were treated with PGI for 3h, KLF4 expression levels remained unchanged in all cases due to the absence of gp78 in the non-stem glioma cells (Fig 4B) . On the contrary, PGI was able to induce KLF4 expression in the patient-derived oncospheres (Fig 4C) . These effects were dependent on gp78 activity since KLF4 induction by PGI was blocked by the presence of P0973 (Fig 4D) .
To study the transcriptional regulation of KLF4 by PGI, we used a luciferase reporter construct containing the -1200/+32 promoter region of human KLF4 gene (Fig 4E) . PGI and P0973 were able to transactivate and suppress the KLF4 reporter constructs respectively, indicating that PGI regulates KLF4 at the transcriptional level. Further, we were able to map the PGIresponsive element to the -520/-50 promoter region, since the -50/+32 region did not respond to PGI and the -520/-50 promoter region was sufficient to be regulated by PGI and P0973 (Fig 4F) . This region contains three consensus SP1-binding elements (SPE) (Fig 4E) . We co-transfected oncospheres with various KLF4 promoter reporters and increasing amounts of SP1 expression plasmid. The results showed that overexpression of SP1 alone increased the activity of the -1200bp and -520bp KLF4 promoters in a dose-dependent manner. The -50bp KLF4 promoter, which does not contain the SP1 sites, was unaffected by SP1 overexpression (Fig S4) . We also mutated the SPE (mutSPE, from GGCGGG to GTTTTG) and observed that the response to PGI was blunted (Fig 4G) , suggesting that an activated SP1 binds to the proximal SPE in the KLF4 promoter to induce transcription. In line with this, knockdown of SP1 abolished the KLF4 response to PGI in oncopsheres (Fig 4H) .
KLF4 mediates the induction of GSCs self-renewal by PGI. To further validate the effects of the PGI-KLF4 pathway on GSC self-renewal, oncospheres were dissociated into single cells and treated with lenti-KLF4, PGI, and/or siKLF4 as indicated. We observed that sphere cells treated with PGI or/and transfected with lenti-KLF4 exhibited increased number of sphere-forming cells for over four passages, whereas untreated cells yielded oncospheres without enhanced self-renewal capacity. The PGI effect was dependent on the induction of KLF4 (Fig 5A and 5B ).
Finally, we tested the potential clinical significance of these findings using in vivo expanded primary tissue from a patient with primary mesenchymal GBM (GBM6). One week after implantation, the tumor-bearing mice were randomized for treatment. The detailed experimental setup is depicted in Fig  5C. All control animals bore large, life-limiting tumors and died within 2 month after implantation. In stark contrast, for the treatment group, tumors quickly regressed and long-term survival was significantly better compared with the control group (Fig 5D and 5E) . Intriguingly, phenotyping of these tumors by immunofluorescence staining revealed a virtually complete elimination of the CD133+GSCs as compared with the control tumors. Thus, interruption of the IL6-KLF4 pathway virtually decreased the tumorigenic potential of GSCs (Fig 5F) . 
Discussion
In this study, we observed that aberrant mesenchymal phenotype is associated with significant enrichment of GSCs and higher self-renewal efficiency. Although emerging evidence has indicated the involvement of mesenchymal transition in CSC development [7, 8] , mesenchymal transformation in the non-stem glioma cells failed to directly trigger reversion to a GSC-like phenotype. Then a question was raised: what is the major factor accounting for the expanded the GSC pool in mesenchymal gliomas? GSCs are a sub-population of glioma cells that possess characteristics associated with neural stem cells (NSCs) [26, 27] . Neural stem cell activity is maintained in niches. Analogously, niches that maintain GSCs also exist [28] . The ability of niche to determine the functional spectrum of NSCs activities suggests that niche microenvironments also beget GSCs functions [29] [30] . Here, we demonstrated that mesenchymal glioma cells generate a specific microenvironment that promotes the self-renewal of GSCs. Recruitment of mesenchymal niche environments is an important hallmark of high-grade gliomas [3] . Indeed, our findings well explain why primary high-grade gliomas are highly aggressive with a rapid fatal progression for the patients.
An understanding of the molecular mechanisms involved in the action of mesenchymal glioma cells on GSC stemness is crucial for design of efficient therapeutic strategies. We showed that the interaction between GSCs and mesenchymal glioma cells is mediated by a paracrine cytokine loop in which PGI plays a pivotal role. This loop requires the simultaneous presence of both cell types but does not require cell-cell contact as shown by transwell and conditioned medium experiments. PGI is tightly linked to tumor generation and poor disease outcome in many cancer types [31] [32] [33] [34] . Our data identified a mechanism implicated in the PGI oncogenic response in human gliomas. PGI, which is secreted by mesenchymal glioma cells, regulates the self-renewal capacity of GSCs. If this paradigm proves more broadly applicable, then mesenchymal glioma cells act as a critical factor in the GSCs niche.
We have also demonstrated that PGI promotes the self-renewal capacity of GSCs through induction of KLF4. KLF4 is well known to be one of the self-renewal genes, such as Oct4 and Nanog, and to play pivotal roles in maintaining stemness of embryonic stem cells [23] . KLF4 also plays crucial roles in maintenance of NSCs, and KLF4 deficiency causes impaired neurogenesis in adult mouse brain [23, 25] . Our report is the first, to our knowledge, to show the significance of the PGI-KLF4 pathway for the maintenance of GSCs. Interruption of the PGI-KLF4 pathway can be translated into an decreased oncogenic capacity of GSCs. Thus, KLF4 is an essential factor for maintenance of GSCs as well as NSCs and embryonic stem cells, supporting the concept that malignant GSCs and normal neural stem cells are closely associated with each other in their biological properties.
Supplementary information is available in the online version of the paper.
Microarray expression analysis. RNA was harvested from the indicated cells. Three independent experiments were performed. Five micrograms of extracted total RNA was used to generate biotinylated complementary RNA (cRNA) following the standard Affymetrix GeneChip protocol. Gene expression analyses used Affymetrix U133 plus 2.0 human oligonucleotide microarrays containing over 47,000 transcripts and variants, including 38,500 well characterized human genes. Hybridizations, washes, and detection were done as recommended by the supplier. CEL files were imported into the ArrayAssist package (Stratagene) and preprocessed using the RMA (robust multiarray analysis) algorithm with the default parameters. Genes were filtered according to the following criterion: AbsFC with respect to their respective control experiments≥2. Genes complying with these criteria were then used for later study.
Protein quantitation and identification. The supernatant samples from the indicated cells were in-gel digested enzymatically and analyzed by LC-MS/MS. The database search was performed using both the X!Tandem and SEQUEST algorithms. Quantification was first performed using Mascot 2.2. Using the Mascot quantification method, protein quantification was only performed on proteins identified by two or more peptides with scores above the identity threshold. Protein differential expression was also assessed at the peptide level. All peptides were used to calculate global mean and S.D. of peptide ratios (47-1/D3). The differentially expressed peptides were used to infer differentially expressed proteins. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55 
